Cagrilintide: difference between revisions
Diff·revision 8 → 9·03:59, 22 Nov 2024
Difference between revision 8 and revision 9 of Cagrilintide. 5 lines changed; the page grew by 532 bytes.
| Revision 8 — 18:11, 1 Nov 2024 Peptide_Pete (talk) correct the molar mass — source gives the free-base figure, we had the salt 2,406 bytes ±0 | Revision 9 — 03:59, 22 Nov 2024 CiteBot (talk) bot: normalise citation format 2,938 bytes +532 | ||
|---|---|---|---|
| 20 | Because the receptor family is unrelated to the incretin receptors, no single molecule can engage both; this is why the semaglutide combination is a co-formulation rather than a unimolecular dual agonist. See [[Dual incretin agonist]].{{r|hay2015}} | 20 | Because the receptor family is unrelated to the incretin receptors, no single molecule can engage both; this is why the semaglutide combination is a co-formulation rather than a unimolecular dual agonist. See [[Dual incretin agonist]].{{r|hay2015}} |
| 21 | 21 | ||
| + | 22 | == Reported findings == | |
| + | 23 | A phase 2 monotherapy trial reported approximately 10% weight reduction at 26 weeks. In combination with semaglutide the reported reduction exceeds that of either component alone; the combination programme is covered at [[CagriSema]].{{r|lau2021}} | |
| + | 24 | ||
| + | 25 | Gastrointestinal adverse events dominate, as with the incretin agonists, and are concentrated during escalation. Whether combining two agents that both delay gastric emptying compounds them is addressed only indirectly by the published designs.{{r|hay2015}} | |
| + | 26 | ||
| 22 | == References == | 27 | == References == |
| 23 | {{reflist}} | 28 | {{reflist}} |